Early phase clinical trials

Early phase studies are often designed and implemented without substantive statistical input. The 3+3 maximum tolerated dose finding design being a classic example. This group aims to improve statistical aspects of early phase studies by bridging the gap between clinical trialists using traditional designs and modern statistical methodologists with many improvements to offer.

We are interested in reaching a consensus within the statistical community of which modern methods should be regarded as standard, and communicating these methods to a wider audience through training and education to increase their use in real-life trials.

Collaborative research enables us to consolidate our knowledge and share expertise. Our research section seeks to undertake collaborative working to promote high quality research by tackling discipline specific issues.

If you would like to be part of a research section or wish to find out more please email the NIHR Statistics Group.

Section leaders

Christina Yap

Group Co-leader, Early Phase Clinical Trials

The Institute of Cancer Research

Simon Bond

Group Co-leader, Early Phase Clinical Trials

Cambridge Clinical Trials Unit

Section committee members

Emily Alger

The Institute of Cancer Research

Haiyan Zheng

University of Bath

Pavel Mozgunov

University of Cambridge

Graham Wheeler

Imperial College London

Previous events

Implementing novel designs in early phase dose-finding trials

CONCORDE: a phase I platform trial using the TiTE-CRM design

Flexible early-phase design for drug combination studies

Implementing a Bivariate Continual Reassessment Method in a Non-Oncology First In Human Trial

A dose-finding design for dual-agent trials with patient-specific continuous doses of one agent: application in an opiate detoxification trial

NIHR Statistics Early Phase Trials Group Meeting 2019

Second Workshop of the NIHR Statistics Group’s Early Phase Trials Research Section